nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—myometrium—ovarian cancer	0.012	0.0434	CbGeAlD
Lithium—GSK3B—embryo—ovarian cancer	0.0113	0.0409	CbGeAlD
Lithium—IMPA1—gonad—ovarian cancer	0.0104	0.0377	CbGeAlD
Lithium—GSK3A—myometrium—ovarian cancer	0.0102	0.037	CbGeAlD
Lithium—IMPA2—uterine cervix—ovarian cancer	0.0093	0.0338	CbGeAlD
Lithium—IMPA1—female reproductive system—ovarian cancer	0.00929	0.0337	CbGeAlD
Lithium—GSK3B—epithelium—ovarian cancer	0.00921	0.0334	CbGeAlD
Lithium—GSK3B—uterine cervix—ovarian cancer	0.00913	0.0331	CbGeAlD
Lithium—IMPA2—decidua—ovarian cancer	0.00886	0.0322	CbGeAlD
Lithium—GSK3B—decidua—ovarian cancer	0.0087	0.0316	CbGeAlD
Lithium—IMPA1—female gonad—ovarian cancer	0.00845	0.0307	CbGeAlD
Lithium—IMPA2—endometrium—ovarian cancer	0.00842	0.0305	CbGeAlD
Lithium—GSK3A—uterine cervix—ovarian cancer	0.00794	0.0288	CbGeAlD
Lithium—GSK3B—gonad—ovarian cancer	0.00766	0.0278	CbGeAlD
Lithium—GSK3B—uterus—ovarian cancer	0.00761	0.0276	CbGeAlD
Lithium—GSK3A—decidua—ovarian cancer	0.00756	0.0274	CbGeAlD
Lithium—IMPA1—testis—ovarian cancer	0.0075	0.0272	CbGeAlD
Lithium—GSK3A—endometrium—ovarian cancer	0.00718	0.0261	CbGeAlD
Lithium—IMPA2—female reproductive system—ovarian cancer	0.00697	0.0253	CbGeAlD
Lithium—GSK3B—female reproductive system—ovarian cancer	0.00684	0.0248	CbGeAlD
Lithium—GSK3A—gonad—ovarian cancer	0.00666	0.0242	CbGeAlD
Lithium—GSK3A—uterus—ovarian cancer	0.00662	0.024	CbGeAlD
Lithium—IMPA2—bone marrow—ovarian cancer	0.00658	0.0239	CbGeAlD
Lithium—GRIA3—testis—ovarian cancer	0.00637	0.0231	CbGeAlD
Lithium—IMPA2—female gonad—ovarian cancer	0.00634	0.023	CbGeAlD
Lithium—IMPA2—vagina—ovarian cancer	0.0063	0.0229	CbGeAlD
Lithium—GSK3B—female gonad—ovarian cancer	0.00622	0.0226	CbGeAlD
Lithium—GSK3B—vagina—ovarian cancer	0.00619	0.0224	CbGeAlD
Lithium—GSK3A—female reproductive system—ovarian cancer	0.00595	0.0216	CbGeAlD
Lithium—IMPA2—testis—ovarian cancer	0.00563	0.0204	CbGeAlD
Lithium—GSK3A—bone marrow—ovarian cancer	0.00561	0.0204	CbGeAlD
Lithium—GSK3B—testis—ovarian cancer	0.00552	0.02	CbGeAlD
Lithium—GSK3A—female gonad—ovarian cancer	0.00541	0.0196	CbGeAlD
Lithium—GSK3A—vagina—ovarian cancer	0.00538	0.0195	CbGeAlD
Lithium—GSK3A—testis—ovarian cancer	0.0048	0.0174	CbGeAlD
Lithium—IMPA2—lymph node—ovarian cancer	0.00408	0.0148	CbGeAlD
Lithium—GSK3B—lymph node—ovarian cancer	0.004	0.0145	CbGeAlD
Lithium—GSK3A—lymph node—ovarian cancer	0.00348	0.0126	CbGeAlD
Lithium—Arthralgia—Topotecan—ovarian cancer	0.000727	0.00353	CcSEcCtD
Lithium—Convulsion—Melphalan—ovarian cancer	0.000724	0.00352	CcSEcCtD
Lithium—Muscular weakness—Paclitaxel—ovarian cancer	0.000719	0.0035	CcSEcCtD
Lithium—Discomfort—Topotecan—ovarian cancer	0.000718	0.00349	CcSEcCtD
Lithium—Lethargy—Docetaxel—ovarian cancer	0.000706	0.00343	CcSEcCtD
Lithium—Oliguria—Epirubicin—ovarian cancer	0.000697	0.00339	CcSEcCtD
Lithium—Dyspepsia—Chlorambucil—ovarian cancer	0.000689	0.00335	CcSEcCtD
Lithium—Oedema—Melphalan—ovarian cancer	0.000682	0.00332	CcSEcCtD
Lithium—Decreased appetite—Chlorambucil—ovarian cancer	0.00068	0.00331	CcSEcCtD
Lithium—Dysarthria—Epirubicin—ovarian cancer	0.000679	0.0033	CcSEcCtD
Lithium—Fatigue—Chlorambucil—ovarian cancer	0.000675	0.00328	CcSEcCtD
Lithium—Angioedema—Vinorelbine—ovarian cancer	0.000667	0.00324	CcSEcCtD
Lithium—Anorexia—Topotecan—ovarian cancer	0.000664	0.00323	CcSEcCtD
Lithium—Vertigo—Vinorelbine—ovarian cancer	0.000656	0.00319	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—ovarian cancer	0.000654	0.00318	CcSEcCtD
Lithium—Anorexia—Melphalan—ovarian cancer	0.00065	0.00316	CcSEcCtD
Lithium—Ataxia—Docetaxel—ovarian cancer	0.00065	0.00316	CcSEcCtD
Lithium—Oliguria—Doxorubicin—ovarian cancer	0.000645	0.00313	CcSEcCtD
Lithium—Feeling abnormal—Chlorambucil—ovarian cancer	0.000645	0.00313	CcSEcCtD
Lithium—Dehydration—Docetaxel—ovarian cancer	0.000643	0.00312	CcSEcCtD
Lithium—Weight increased—Paclitaxel—ovarian cancer	0.000642	0.00312	CcSEcCtD
Lithium—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00064	0.00311	CcSEcCtD
Lithium—Weight decreased—Paclitaxel—ovarian cancer	0.000638	0.0031	CcSEcCtD
Lithium—Hypotension—Melphalan—ovarian cancer	0.000637	0.0031	CcSEcCtD
Lithium—Hyperglycaemia—Paclitaxel—ovarian cancer	0.000636	0.00309	CcSEcCtD
Lithium—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000635	0.00309	CcSEcCtD
Lithium—Dry skin—Docetaxel—ovarian cancer	0.000634	0.00308	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—ovarian cancer	0.000628	0.00305	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—ovarian cancer	0.000624	0.00303	CcSEcCtD
Lithium—Arthralgia—Vinorelbine—ovarian cancer	0.000622	0.00302	CcSEcCtD
Lithium—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000622	0.00302	CcSEcCtD
Lithium—Abdominal pain—Chlorambucil—ovarian cancer	0.000619	0.00301	CcSEcCtD
Lithium—Body temperature increased—Chlorambucil—ovarian cancer	0.000619	0.00301	CcSEcCtD
Lithium—Discomfort—Vinorelbine—ovarian cancer	0.000614	0.00299	CcSEcCtD
Lithium—Dyspepsia—Topotecan—ovarian cancer	0.000613	0.00298	CcSEcCtD
Lithium—Decreased appetite—Topotecan—ovarian cancer	0.000606	0.00294	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—ovarian cancer	0.000605	0.00294	CcSEcCtD
Lithium—Fatigue—Topotecan—ovarian cancer	0.000601	0.00292	CcSEcCtD
Lithium—Dyspepsia—Melphalan—ovarian cancer	0.000601	0.00292	CcSEcCtD
Lithium—Decreased appetite—Melphalan—ovarian cancer	0.000593	0.00288	CcSEcCtD
Lithium—Fatigue—Melphalan—ovarian cancer	0.000588	0.00286	CcSEcCtD
Lithium—Coma—Epirubicin—ovarian cancer	0.000587	0.00285	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.000577	0.00281	CcSEcCtD
Lithium—Bradycardia—Paclitaxel—ovarian cancer	0.000574	0.00279	CcSEcCtD
Lithium—Feeling abnormal—Topotecan—ovarian cancer	0.000574	0.00279	CcSEcCtD
Lithium—Gastrointestinal pain—Topotecan—ovarian cancer	0.00057	0.00277	CcSEcCtD
Lithium—Anorexia—Vinorelbine—ovarian cancer	0.000568	0.00276	CcSEcCtD
Lithium—Hypertonia—Epirubicin—ovarian cancer	0.000563	0.00274	CcSEcCtD
Lithium—Asthenia—Chlorambucil—ovarian cancer	0.000562	0.00273	CcSEcCtD
Lithium—Hypotension—Vinorelbine—ovarian cancer	0.000557	0.00271	CcSEcCtD
Lithium—Body temperature increased—Topotecan—ovarian cancer	0.000551	0.00268	CcSEcCtD
Lithium—Abdominal pain—Topotecan—ovarian cancer	0.000551	0.00268	CcSEcCtD
Lithium—Weight increased—Docetaxel—ovarian cancer	0.000544	0.00264	CcSEcCtD
Lithium—Coma—Doxorubicin—ovarian cancer	0.000543	0.00264	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000543	0.00264	CcSEcCtD
Lithium—Weight decreased—Docetaxel—ovarian cancer	0.000541	0.00263	CcSEcCtD
Lithium—Diarrhoea—Chlorambucil—ovarian cancer	0.000535	0.0026	CcSEcCtD
Lithium—Tinnitus—Paclitaxel—ovarian cancer	0.000526	0.00256	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—ovarian cancer	0.000521	0.00253	CcSEcCtD
Lithium—Decreased appetite—Vinorelbine—ovarian cancer	0.000518	0.00252	CcSEcCtD
Lithium—Fatigue—Vinorelbine—ovarian cancer	0.000514	0.0025	CcSEcCtD
Lithium—Arrhythmia—Paclitaxel—ovarian cancer	0.000504	0.00245	CcSEcCtD
Lithium—Asthenia—Topotecan—ovarian cancer	0.0005	0.00243	CcSEcCtD
Lithium—Alopecia—Paclitaxel—ovarian cancer	0.000499	0.00242	CcSEcCtD
Lithium—Vomiting—Chlorambucil—ovarian cancer	0.000498	0.00242	CcSEcCtD
Lithium—Feeling abnormal—Vinorelbine—ovarian cancer	0.000491	0.00239	CcSEcCtD
Lithium—Asthenia—Melphalan—ovarian cancer	0.000489	0.00238	CcSEcCtD
Lithium—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000487	0.00237	CcSEcCtD
Lithium—Flatulence—Paclitaxel—ovarian cancer	0.000484	0.00235	CcSEcCtD
Lithium—Dysgeusia—Paclitaxel—ovarian cancer	0.000481	0.00234	CcSEcCtD
Lithium—Diarrhoea—Topotecan—ovarian cancer	0.000477	0.00232	CcSEcCtD
Lithium—Lethargy—Epirubicin—ovarian cancer	0.000476	0.00231	CcSEcCtD
Lithium—Abdominal pain—Vinorelbine—ovarian cancer	0.000471	0.00229	CcSEcCtD
Lithium—Body temperature increased—Vinorelbine—ovarian cancer	0.000471	0.00229	CcSEcCtD
Lithium—Diarrhoea—Melphalan—ovarian cancer	0.000467	0.00227	CcSEcCtD
Lithium—Nausea—Chlorambucil—ovarian cancer	0.000465	0.00226	CcSEcCtD
Lithium—Vision blurred—Paclitaxel—ovarian cancer	0.000463	0.00225	CcSEcCtD
Lithium—Dizziness—Topotecan—ovarian cancer	0.000461	0.00224	CcSEcCtD
Lithium—Tremor—Paclitaxel—ovarian cancer	0.00046	0.00224	CcSEcCtD
Lithium—Agitation—Paclitaxel—ovarian cancer	0.000451	0.00219	CcSEcCtD
Lithium—Angioedema—Paclitaxel—ovarian cancer	0.000449	0.00218	CcSEcCtD
Lithium—Vomiting—Topotecan—ovarian cancer	0.000443	0.00215	CcSEcCtD
Lithium—Vertigo—Paclitaxel—ovarian cancer	0.000441	0.00214	CcSEcCtD
Lithium—Syncope—Paclitaxel—ovarian cancer	0.000441	0.00214	CcSEcCtD
Lithium—Lethargy—Doxorubicin—ovarian cancer	0.00044	0.00214	CcSEcCtD
Lithium—Rash—Topotecan—ovarian cancer	0.000439	0.00214	CcSEcCtD
Lithium—Dermatitis—Topotecan—ovarian cancer	0.000439	0.00213	CcSEcCtD
Lithium—Ataxia—Epirubicin—ovarian cancer	0.000438	0.00213	CcSEcCtD
Lithium—Headache—Topotecan—ovarian cancer	0.000436	0.00212	CcSEcCtD
Lithium—Vomiting—Melphalan—ovarian cancer	0.000434	0.00211	CcSEcCtD
Lithium—Dehydration—Epirubicin—ovarian cancer	0.000434	0.00211	CcSEcCtD
Lithium—Loss of consciousness—Paclitaxel—ovarian cancer	0.000432	0.0021	CcSEcCtD
Lithium—Rash—Melphalan—ovarian cancer	0.00043	0.00209	CcSEcCtD
Lithium—Dermatitis—Melphalan—ovarian cancer	0.00043	0.00209	CcSEcCtD
Lithium—Asthenia—Vinorelbine—ovarian cancer	0.000428	0.00208	CcSEcCtD
Lithium—Dry skin—Epirubicin—ovarian cancer	0.000427	0.00208	CcSEcCtD
Lithium—Arrhythmia—Docetaxel—ovarian cancer	0.000427	0.00208	CcSEcCtD
Lithium—Convulsion—Paclitaxel—ovarian cancer	0.000426	0.00207	CcSEcCtD
Lithium—Alopecia—Docetaxel—ovarian cancer	0.000423	0.00205	CcSEcCtD
Lithium—Arthralgia—Paclitaxel—ovarian cancer	0.000418	0.00203	CcSEcCtD
Lithium—Nausea—Topotecan—ovarian cancer	0.000414	0.00201	CcSEcCtD
Lithium—Discomfort—Paclitaxel—ovarian cancer	0.000413	0.00201	CcSEcCtD
Lithium—Gastritis—Epirubicin—ovarian cancer	0.000413	0.00201	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—ovarian cancer	0.000411	0.002	CcSEcCtD
Lithium—Dry mouth—Paclitaxel—ovarian cancer	0.000409	0.00199	CcSEcCtD
Lithium—Diarrhoea—Vinorelbine—ovarian cancer	0.000408	0.00198	CcSEcCtD
Lithium—Dysgeusia—Docetaxel—ovarian cancer	0.000408	0.00198	CcSEcCtD
Lithium—Ataxia—Doxorubicin—ovarian cancer	0.000406	0.00197	CcSEcCtD
Lithium—Nausea—Melphalan—ovarian cancer	0.000405	0.00197	CcSEcCtD
Lithium—Confusional state—Paclitaxel—ovarian cancer	0.000404	0.00196	CcSEcCtD
Lithium—Dehydration—Doxorubicin—ovarian cancer	0.000401	0.00195	CcSEcCtD
Lithium—Oedema—Paclitaxel—ovarian cancer	0.000401	0.00195	CcSEcCtD
Lithium—Dry skin—Doxorubicin—ovarian cancer	0.000395	0.00192	CcSEcCtD
Lithium—Shock—Paclitaxel—ovarian cancer	0.000394	0.00192	CcSEcCtD
Lithium—Dizziness—Vinorelbine—ovarian cancer	0.000394	0.00192	CcSEcCtD
Lithium—Anorexia—Paclitaxel—ovarian cancer	0.000382	0.00186	CcSEcCtD
Lithium—Gastritis—Doxorubicin—ovarian cancer	0.000382	0.00186	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—ovarian cancer	0.000381	0.00185	CcSEcCtD
Lithium—Vomiting—Vinorelbine—ovarian cancer	0.000379	0.00184	CcSEcCtD
Lithium—Rash—Vinorelbine—ovarian cancer	0.000376	0.00183	CcSEcCtD
Lithium—Dermatitis—Vinorelbine—ovarian cancer	0.000375	0.00182	CcSEcCtD
Lithium—Hypotension—Paclitaxel—ovarian cancer	0.000375	0.00182	CcSEcCtD
Lithium—Headache—Vinorelbine—ovarian cancer	0.000373	0.00181	CcSEcCtD
Lithium—Syncope—Docetaxel—ovarian cancer	0.000373	0.00181	CcSEcCtD
Lithium—Weight increased—Epirubicin—ovarian cancer	0.000367	0.00178	CcSEcCtD
Lithium—Loss of consciousness—Docetaxel—ovarian cancer	0.000366	0.00178	CcSEcCtD
Lithium—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000365	0.00178	CcSEcCtD
Lithium—Weight decreased—Epirubicin—ovarian cancer	0.000365	0.00177	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—ovarian cancer	0.000364	0.00177	CcSEcCtD
Lithium—Convulsion—Docetaxel—ovarian cancer	0.000361	0.00175	CcSEcCtD
Lithium—Drowsiness—Epirubicin—ovarian cancer	0.000359	0.00175	CcSEcCtD
Lithium—Somnolence—Paclitaxel—ovarian cancer	0.000356	0.00173	CcSEcCtD
Lithium—Arthralgia—Docetaxel—ovarian cancer	0.000354	0.00172	CcSEcCtD
Lithium—Nausea—Vinorelbine—ovarian cancer	0.000354	0.00172	CcSEcCtD
Lithium—Dyspepsia—Paclitaxel—ovarian cancer	0.000353	0.00172	CcSEcCtD
Lithium—Decreased appetite—Paclitaxel—ovarian cancer	0.000348	0.00169	CcSEcCtD
Lithium—Dry mouth—Docetaxel—ovarian cancer	0.000347	0.00168	CcSEcCtD
Lithium—Fatigue—Paclitaxel—ovarian cancer	0.000346	0.00168	CcSEcCtD
Lithium—Confusional state—Docetaxel—ovarian cancer	0.000343	0.00167	CcSEcCtD
Lithium—Oedema—Docetaxel—ovarian cancer	0.00034	0.00165	CcSEcCtD
Lithium—Weight increased—Doxorubicin—ovarian cancer	0.000339	0.00165	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—ovarian cancer	0.000337	0.00164	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000336	0.00163	CcSEcCtD
Lithium—Shock—Docetaxel—ovarian cancer	0.000334	0.00162	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—ovarian cancer	0.000333	0.00162	CcSEcCtD
Lithium—Feeling abnormal—Paclitaxel—ovarian cancer	0.00033	0.00161	CcSEcCtD
Lithium—Bradycardia—Epirubicin—ovarian cancer	0.000328	0.0016	CcSEcCtD
Lithium—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000328	0.00159	CcSEcCtD
Lithium—Anorexia—Docetaxel—ovarian cancer	0.000324	0.00157	CcSEcCtD
Lithium—Hypotension—Docetaxel—ovarian cancer	0.000318	0.00154	CcSEcCtD
Lithium—Body temperature increased—Paclitaxel—ovarian cancer	0.000317	0.00154	CcSEcCtD
Lithium—Abdominal pain—Paclitaxel—ovarian cancer	0.000317	0.00154	CcSEcCtD
Lithium—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00031	0.0015	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—ovarian cancer	0.000304	0.00148	CcSEcCtD
Lithium—Somnolence—Docetaxel—ovarian cancer	0.000302	0.00147	CcSEcCtD
Lithium—Tinnitus—Epirubicin—ovarian cancer	0.000301	0.00146	CcSEcCtD
Lithium—Dyspepsia—Docetaxel—ovarian cancer	0.000299	0.00145	CcSEcCtD
Lithium—Decreased appetite—Docetaxel—ovarian cancer	0.000295	0.00144	CcSEcCtD
Lithium—Fatigue—Docetaxel—ovarian cancer	0.000293	0.00142	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—ovarian cancer	0.000288	0.0014	CcSEcCtD
Lithium—Asthenia—Paclitaxel—ovarian cancer	0.000288	0.0014	CcSEcCtD
Lithium—Alopecia—Epirubicin—ovarian cancer	0.000285	0.00139	CcSEcCtD
Lithium—Feeling abnormal—Docetaxel—ovarian cancer	0.00028	0.00136	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—ovarian cancer	0.000278	0.00135	CcSEcCtD
Lithium—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000278	0.00135	CcSEcCtD
Lithium—Flatulence—Epirubicin—ovarian cancer	0.000277	0.00134	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—ovarian cancer	0.000275	0.00134	CcSEcCtD
Lithium—Diarrhoea—Paclitaxel—ovarian cancer	0.000274	0.00133	CcSEcCtD
Lithium—Abdominal pain—Docetaxel—ovarian cancer	0.000269	0.00131	CcSEcCtD
Lithium—Body temperature increased—Docetaxel—ovarian cancer	0.000269	0.00131	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—ovarian cancer	0.000267	0.0013	CcSEcCtD
Lithium—Dizziness—Paclitaxel—ovarian cancer	0.000265	0.00129	CcSEcCtD
Lithium—Vision blurred—Epirubicin—ovarian cancer	0.000265	0.00129	CcSEcCtD
Lithium—Alopecia—Doxorubicin—ovarian cancer	0.000264	0.00128	CcSEcCtD
Lithium—Agitation—Epirubicin—ovarian cancer	0.000258	0.00125	CcSEcCtD
Lithium—Flatulence—Doxorubicin—ovarian cancer	0.000256	0.00124	CcSEcCtD
Lithium—Vomiting—Paclitaxel—ovarian cancer	0.000255	0.00124	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—ovarian cancer	0.000254	0.00124	CcSEcCtD
Lithium—Rash—Paclitaxel—ovarian cancer	0.000253	0.00123	CcSEcCtD
Lithium—Dermatitis—Paclitaxel—ovarian cancer	0.000253	0.00123	CcSEcCtD
Lithium—Vertigo—Epirubicin—ovarian cancer	0.000252	0.00123	CcSEcCtD
Lithium—Syncope—Epirubicin—ovarian cancer	0.000252	0.00122	CcSEcCtD
Lithium—Headache—Paclitaxel—ovarian cancer	0.000251	0.00122	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—ovarian cancer	0.000247	0.0012	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—ovarian cancer	0.000245	0.00119	CcSEcCtD
Lithium—Asthenia—Docetaxel—ovarian cancer	0.000244	0.00118	CcSEcCtD
Lithium—Convulsion—Epirubicin—ovarian cancer	0.000243	0.00118	CcSEcCtD
Lithium—Arthralgia—Epirubicin—ovarian cancer	0.000239	0.00116	CcSEcCtD
Lithium—Agitation—Doxorubicin—ovarian cancer	0.000239	0.00116	CcSEcCtD
Lithium—Nausea—Paclitaxel—ovarian cancer	0.000238	0.00116	CcSEcCtD
Lithium—Discomfort—Epirubicin—ovarian cancer	0.000236	0.00115	CcSEcCtD
Lithium—Dry mouth—Epirubicin—ovarian cancer	0.000234	0.00114	CcSEcCtD
Lithium—Vertigo—Doxorubicin—ovarian cancer	0.000233	0.00113	CcSEcCtD
Lithium—Syncope—Doxorubicin—ovarian cancer	0.000233	0.00113	CcSEcCtD
Lithium—Diarrhoea—Docetaxel—ovarian cancer	0.000232	0.00113	CcSEcCtD
Lithium—Confusional state—Epirubicin—ovarian cancer	0.000231	0.00112	CcSEcCtD
Lithium—Oedema—Epirubicin—ovarian cancer	0.000229	0.00111	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—ovarian cancer	0.000228	0.00111	CcSEcCtD
Lithium—Shock—Epirubicin—ovarian cancer	0.000225	0.0011	CcSEcCtD
Lithium—Convulsion—Doxorubicin—ovarian cancer	0.000225	0.00109	CcSEcCtD
Lithium—Dizziness—Docetaxel—ovarian cancer	0.000225	0.00109	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—ovarian cancer	0.000221	0.00108	CcSEcCtD
Lithium—Discomfort—Doxorubicin—ovarian cancer	0.000219	0.00106	CcSEcCtD
Lithium—Anorexia—Epirubicin—ovarian cancer	0.000218	0.00106	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—ovarian cancer	0.000216	0.00105	CcSEcCtD
Lithium—Vomiting—Docetaxel—ovarian cancer	0.000216	0.00105	CcSEcCtD
Lithium—Rash—Docetaxel—ovarian cancer	0.000214	0.00104	CcSEcCtD
Lithium—Hypotension—Epirubicin—ovarian cancer	0.000214	0.00104	CcSEcCtD
Lithium—Dermatitis—Docetaxel—ovarian cancer	0.000214	0.00104	CcSEcCtD
Lithium—Confusional state—Doxorubicin—ovarian cancer	0.000214	0.00104	CcSEcCtD
Lithium—Headache—Docetaxel—ovarian cancer	0.000213	0.00103	CcSEcCtD
Lithium—Oedema—Doxorubicin—ovarian cancer	0.000212	0.00103	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000209	0.00101	CcSEcCtD
Lithium—Shock—Doxorubicin—ovarian cancer	0.000209	0.00101	CcSEcCtD
Lithium—Somnolence—Epirubicin—ovarian cancer	0.000204	0.00099	CcSEcCtD
Lithium—Anorexia—Doxorubicin—ovarian cancer	0.000202	0.000982	CcSEcCtD
Lithium—Nausea—Docetaxel—ovarian cancer	0.000202	0.000981	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—ovarian cancer	0.000202	0.000981	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—ovarian cancer	0.000199	0.000968	CcSEcCtD
Lithium—Hypotension—Doxorubicin—ovarian cancer	0.000198	0.000963	CcSEcCtD
Lithium—Fatigue—Epirubicin—ovarian cancer	0.000198	0.00096	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000193	0.000939	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—ovarian cancer	0.000189	0.000918	CcSEcCtD
Lithium—Somnolence—Doxorubicin—ovarian cancer	0.000189	0.000916	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000187	0.000911	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—ovarian cancer	0.000187	0.000907	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—ovarian cancer	0.000184	0.000896	CcSEcCtD
Lithium—Fatigue—Doxorubicin—ovarian cancer	0.000183	0.000889	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—ovarian cancer	0.000181	0.000881	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—ovarian cancer	0.000181	0.000881	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—ovarian cancer	0.000175	0.000849	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000173	0.000843	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—ovarian cancer	0.000168	0.000815	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—ovarian cancer	0.000168	0.000815	CcSEcCtD
Lithium—Asthenia—Epirubicin—ovarian cancer	0.000164	0.000799	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—ovarian cancer	0.000157	0.000762	CcSEcCtD
Lithium—Asthenia—Doxorubicin—ovarian cancer	0.000152	0.00074	CcSEcCtD
Lithium—Dizziness—Epirubicin—ovarian cancer	0.000152	0.000737	CcSEcCtD
Lithium—Vomiting—Epirubicin—ovarian cancer	0.000146	0.000708	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—ovarian cancer	0.000145	0.000705	CcSEcCtD
Lithium—Rash—Epirubicin—ovarian cancer	0.000145	0.000702	CcSEcCtD
Lithium—Dermatitis—Epirubicin—ovarian cancer	0.000144	0.000702	CcSEcCtD
Lithium—Headache—Epirubicin—ovarian cancer	0.000144	0.000698	CcSEcCtD
Lithium—Dizziness—Doxorubicin—ovarian cancer	0.00014	0.000682	CcSEcCtD
Lithium—Nausea—Epirubicin—ovarian cancer	0.000136	0.000662	CcSEcCtD
Lithium—Vomiting—Doxorubicin—ovarian cancer	0.000135	0.000655	CcSEcCtD
Lithium—Rash—Doxorubicin—ovarian cancer	0.000134	0.00065	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—ovarian cancer	0.000134	0.000649	CcSEcCtD
Lithium—Headache—Doxorubicin—ovarian cancer	0.000133	0.000646	CcSEcCtD
Lithium—Nausea—Doxorubicin—ovarian cancer	0.000126	0.000612	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—PARP1—ovarian cancer	8.37e-05	0.000161	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—ovarian cancer	8.36e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1B—ovarian cancer	8.34e-05	0.000161	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—ovarian cancer	8.28e-05	0.00016	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—ovarian cancer	8.2e-05	0.000158	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—ovarian cancer	8.11e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—ovarian cancer	8.08e-05	0.000156	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MAPK3—ovarian cancer	8.01e-05	0.000154	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—ovarian cancer	7.99e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—ovarian cancer	7.95e-05	0.000153	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—ovarian cancer	7.93e-05	0.000153	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—ovarian cancer	7.88e-05	0.000152	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—ovarian cancer	7.84e-05	0.000151	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CD—ovarian cancer	7.84e-05	0.000151	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—ovarian cancer	7.77e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Immune System—PPP2R1A—ovarian cancer	7.76e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—ovarian cancer	7.76e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—ovarian cancer	7.7e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—ovarian cancer	7.68e-05	0.000148	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR4—ovarian cancer	7.63e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—YAP1—ovarian cancer	7.62e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MAPK1—ovarian cancer	7.62e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—ovarian cancer	7.62e-05	0.000147	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—ovarian cancer	7.57e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—ovarian cancer	7.53e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CD—ovarian cancer	7.53e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—XIAP—ovarian cancer	7.47e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—ovarian cancer	7.42e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6ST—ovarian cancer	7.32e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—ovarian cancer	7.31e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMARCA4—ovarian cancer	7.28e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—ovarian cancer	7.2e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—ovarian cancer	7.18e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Disease—PPP2R1A—ovarian cancer	7.17e-05	0.000138	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—ovarian cancer	7.17e-05	0.000138	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—ovarian cancer	7.13e-05	0.000137	CbGpPWpGaD
Lithium—GSK3A—Disease—CAV1—ovarian cancer	7.13e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EREG—ovarian cancer	7.1e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—ovarian cancer	6.93e-05	0.000134	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—ovarian cancer	6.92e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—ovarian cancer	6.9e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—ovarian cancer	6.86e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—ovarian cancer	6.85e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MTOR—ovarian cancer	6.84e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CB—ovarian cancer	6.84e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK3—ovarian cancer	6.83e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PPP2R1A—ovarian cancer	6.79e-05	0.000131	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—ovarian cancer	6.76e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6ST—ovarian cancer	6.76e-05	0.00013	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—ovarian cancer	6.75e-05	0.00013	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—ovarian cancer	6.73e-05	0.00013	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—ovarian cancer	6.67e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PGR—ovarian cancer	6.66e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—ovarian cancer	6.65e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CB—ovarian cancer	6.56e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—MTOR—ovarian cancer	6.56e-05	0.000127	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK1—ovarian cancer	6.5e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—ovarian cancer	6.5e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Disease—APC—ovarian cancer	6.49e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—ovarian cancer	6.47e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—ovarian cancer	6.47e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1B—ovarian cancer	6.41e-05	0.000124	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—ovarian cancer	6.24e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PARP1—ovarian cancer	6.19e-05	0.000119	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—ovarian cancer	6.18e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CD—ovarian cancer	6.18e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1B—ovarian cancer	6.16e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—ovarian cancer	6.14e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—ovarian cancer	6.12e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—ovarian cancer	6.06e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—ovarian cancer	6.04e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—ovarian cancer	5.98e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—ovarian cancer	5.97e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—ovarian cancer	5.97e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—ovarian cancer	5.91e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—ovarian cancer	5.89e-05	0.000114	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—ovarian cancer	5.85e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MAPK3—ovarian cancer	5.71e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CD—ovarian cancer	5.71e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—ovarian cancer	5.69e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—ovarian cancer	5.67e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—ovarian cancer	5.64e-05	0.000109	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—ovarian cancer	5.64e-05	0.000109	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—ovarian cancer	5.51e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—ovarian cancer	5.5e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—ovarian cancer	5.46e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MAPK1—ovarian cancer	5.44e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—ovarian cancer	5.44e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—ovarian cancer	5.41e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6ST—ovarian cancer	5.41e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—ovarian cancer	5.4e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Immune System—MTOR—ovarian cancer	5.39e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CB—ovarian cancer	5.39e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—ovarian cancer	5.27e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Disease—CAV1—ovarian cancer	5.27e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—ovarian cancer	5.22e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—ovarian cancer	5.14e-05	9.9e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—ovarian cancer	5.06e-05	9.76e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—ovarian cancer	5.06e-05	9.75e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK3—ovarian cancer	5.05e-05	9.73e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—ovarian cancer	5.04e-05	9.72e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PPP2R1A—ovarian cancer	5.02e-05	9.68e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—ovarian cancer	5.01e-05	9.66e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—ovarian cancer	4.99e-05	9.63e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6ST—ovarian cancer	4.99e-05	9.63e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CAV1—ovarian cancer	4.99e-05	9.62e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CB—ovarian cancer	4.97e-05	9.59e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MTOR—ovarian cancer	4.97e-05	9.59e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—ovarian cancer	4.95e-05	9.54e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—ovarian cancer	4.81e-05	9.27e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK1—ovarian cancer	4.8e-05	9.26e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—ovarian cancer	4.8e-05	9.26e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—ovarian cancer	4.8e-05	9.25e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—ovarian cancer	4.78e-05	9.22e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—ovarian cancer	4.78e-05	9.21e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6ST—ovarian cancer	4.73e-05	9.12e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—ovarian cancer	4.67e-05	9e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—ovarian cancer	4.66e-05	8.98e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—ovarian cancer	4.61e-05	8.89e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—ovarian cancer	4.61e-05	8.88e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CD—ovarian cancer	4.57e-05	8.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—ovarian cancer	4.55e-05	8.76e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—ovarian cancer	4.55e-05	8.76e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—ovarian cancer	4.54e-05	8.74e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—ovarian cancer	4.42e-05	8.53e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—ovarian cancer	4.41e-05	8.5e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—ovarian cancer	4.37e-05	8.42e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—ovarian cancer	4.36e-05	8.4e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—ovarian cancer	4.3e-05	8.29e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CD—ovarian cancer	4.22e-05	8.13e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—ovarian cancer	4.18e-05	8.05e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—ovarian cancer	4.17e-05	8.03e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—ovarian cancer	4.16e-05	8.03e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—ovarian cancer	4.15e-05	8.01e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—ovarian cancer	4.03e-05	7.78e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—ovarian cancer	4e-05	7.71e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CD—ovarian cancer	4e-05	7.7e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—ovarian cancer	3.99e-05	7.69e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CB—ovarian cancer	3.98e-05	7.68e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MTOR—ovarian cancer	3.98e-05	7.68e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK3—ovarian cancer	3.98e-05	7.67e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—ovarian cancer	3.86e-05	7.43e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—ovarian cancer	3.85e-05	7.43e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—ovarian cancer	3.84e-05	7.41e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—ovarian cancer	3.83e-05	7.39e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK1—ovarian cancer	3.78e-05	7.3e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—ovarian cancer	3.78e-05	7.3e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—ovarian cancer	3.74e-05	7.2e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—ovarian cancer	3.72e-05	7.18e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—ovarian cancer	3.7e-05	7.14e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—ovarian cancer	3.69e-05	7.11e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CAV1—ovarian cancer	3.69e-05	7.11e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTOR—ovarian cancer	3.68e-05	7.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CB—ovarian cancer	3.68e-05	7.09e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK3—ovarian cancer	3.67e-05	7.08e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—ovarian cancer	3.66e-05	7.05e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—ovarian cancer	3.57e-05	6.89e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—ovarian cancer	3.57e-05	6.89e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—ovarian cancer	3.55e-05	6.85e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—ovarian cancer	3.53e-05	6.81e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—ovarian cancer	3.53e-05	6.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6ST—ovarian cancer	3.5e-05	6.74e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK1—ovarian cancer	3.49e-05	6.74e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—ovarian cancer	3.49e-05	6.74e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MTOR—ovarian cancer	3.48e-05	6.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CB—ovarian cancer	3.48e-05	6.72e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—ovarian cancer	3.45e-05	6.65e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—ovarian cancer	3.44e-05	6.63e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—ovarian cancer	3.4e-05	6.56e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—ovarian cancer	3.36e-05	6.48e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—ovarian cancer	3.36e-05	6.48e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—ovarian cancer	3.35e-05	6.45e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—ovarian cancer	3.3e-05	6.36e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—ovarian cancer	3.28e-05	6.33e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—ovarian cancer	3.27e-05	6.3e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—ovarian cancer	3.27e-05	6.3e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—ovarian cancer	3.26e-05	6.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—ovarian cancer	3.2e-05	6.18e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—ovarian cancer	3.2e-05	6.17e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—ovarian cancer	3.18e-05	6.12e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—ovarian cancer	3.12e-05	6.01e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—ovarian cancer	3.09e-05	5.95e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—ovarian cancer	3.08e-05	5.93e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—ovarian cancer	3.07e-05	5.92e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—ovarian cancer	3.04e-05	5.86e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—ovarian cancer	3.03e-05	5.85e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—ovarian cancer	3.03e-05	5.84e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—ovarian cancer	3.01e-05	5.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CD—ovarian cancer	2.95e-05	5.69e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK3—ovarian cancer	2.94e-05	5.67e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—ovarian cancer	2.91e-05	5.61e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—ovarian cancer	2.84e-05	5.48e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—ovarian cancer	2.83e-05	5.46e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—ovarian cancer	2.81e-05	5.41e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK1—ovarian cancer	2.8e-05	5.39e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—ovarian cancer	2.8e-05	5.39e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—ovarian cancer	2.72e-05	5.24e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK3—ovarian cancer	2.71e-05	5.23e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—ovarian cancer	2.69e-05	5.19e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—ovarian cancer	2.69e-05	5.18e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—ovarian cancer	2.69e-05	5.18e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—ovarian cancer	2.68e-05	5.17e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—ovarian cancer	2.64e-05	5.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—ovarian cancer	2.64e-05	5.09e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—ovarian cancer	2.61e-05	5.03e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK1—ovarian cancer	2.58e-05	4.98e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—ovarian cancer	2.58e-05	4.98e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MTOR—ovarian cancer	2.57e-05	4.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CB—ovarian cancer	2.57e-05	4.96e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK3—ovarian cancer	2.57e-05	4.96e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—ovarian cancer	2.5e-05	4.82e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—ovarian cancer	2.48e-05	4.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—ovarian cancer	2.47e-05	4.77e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK1—ovarian cancer	2.45e-05	4.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—ovarian cancer	2.45e-05	4.72e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—ovarian cancer	2.44e-05	4.7e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—ovarian cancer	2.43e-05	4.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—ovarian cancer	2.42e-05	4.66e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—ovarian cancer	2.37e-05	4.56e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—ovarian cancer	2.36e-05	4.56e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—ovarian cancer	2.31e-05	4.46e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—ovarian cancer	2.3e-05	4.44e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—ovarian cancer	2.28e-05	4.4e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—ovarian cancer	2.25e-05	4.33e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—ovarian cancer	2.24e-05	4.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—ovarian cancer	2.24e-05	4.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—ovarian cancer	2.22e-05	4.29e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—ovarian cancer	2.15e-05	4.14e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—ovarian cancer	2.12e-05	4.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—ovarian cancer	2.07e-05	4e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—ovarian cancer	2.05e-05	3.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—ovarian cancer	2.01e-05	3.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—ovarian cancer	1.99e-05	3.84e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—ovarian cancer	1.98e-05	3.83e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—ovarian cancer	1.98e-05	3.83e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—ovarian cancer	1.98e-05	3.82e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—ovarian cancer	1.96e-05	3.79e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK3—ovarian cancer	1.9e-05	3.66e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—ovarian cancer	1.88e-05	3.63e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—ovarian cancer	1.85e-05	3.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—ovarian cancer	1.83e-05	3.53e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK1—ovarian cancer	1.81e-05	3.49e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—ovarian cancer	1.81e-05	3.49e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—ovarian cancer	1.73e-05	3.34e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—ovarian cancer	1.71e-05	3.29e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—ovarian cancer	1.57e-05	3.03e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—ovarian cancer	1.52e-05	2.93e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—ovarian cancer	1.45e-05	2.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—ovarian cancer	1.39e-05	2.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—ovarian cancer	1.28e-05	2.47e-05	CbGpPWpGaD
